FindTrial
Sign In

BHV-0223

DRUG2 trials

Sponsors

Yale University, Biohaven Pharmaceuticals, Inc.

Conditions

ALSAmyotrophic Lateral SclerosisLou Gehrig DiseaseLou Gehrig's DiseaseLou-Gehrigs DiseaseMotor Neuron Disease, Amyotrophic Lateral SclerosisPerformance AnxietySocial Anxiety Disorder

Phase 1

Open-label Study to Evaluate Safety, Tolerability and PK of BHV-0223 in ALS
CompletedNCT03520517
Biohaven Pharmaceuticals, Inc.ALS, Amyotrophic Lateral Sclerosis, Lou Gehrig Disease +3
Start: 2018-02-02End: 2018-10-08Updated: 2022-10-06

Phase 2

Acute Anxiolytic Effects of Riluzole on Subjects With Social Anxiety Disorder
CompletedNCT03017508
Yale UniversityPerformance Anxiety, Social Anxiety Disorder
Start: 2017-01-31End: 2021-01-29Updated: 2021-05-20